10-Q: Enhabit Q3 2025: Profit Rebound Amidst Hospice Growth

Enhabit, Inc. reported a significant turnaround in net income for Q3 2025, driven by strong Hospice segment growth and cost control efforts, despite proposed Medicare payment cuts for Home Health.

Summary

• Net income attributable to Enhabit, Inc. was $11.1 million for the three months ended September 30, 2025, a substantial improvement from a net loss of $110.2 million in the prior year period.
• Net service revenue increased by 3.9% to $263.6 million for Q3 2025, compared to $253.6 million in Q3 2024.
• The Hospice segment's net service revenue grew by 20.0% to $63.1 million in Q3 2025, driven by a 12.6% increase in average daily census and a 6.7% improvement in revenue per patient day.
• The Home Health segment's net service revenue slightly decreased by 0.2% to $200.5 million in Q3 2025, primarily due to a 3.7% decrease in unit revenue per patient day, partially offset by a 3.7% increase in average daily census.
• Operating income was $16.8 million for Q3 2025, a significant improvement from an operating loss of $98.0 million in Q3 2024, which included a $107.9 million goodwill impairment.
• Adjusted EBITDA increased to $27.0 million for Q3 2025, up from $24.5 million in Q3 2024.
• Cash and cash equivalents increased to $56.9 million as of September 30, 2025, from $28.4 million at December 31, 2024.
• The company sold its investment interest in TVG Holdings, LLC for approximately $21 million on March 19, 2025, recording a gain of $19.3 million, and used $20.0 million of the proceeds to reduce debt.
• The Centers for Medicare and Medicaid Services (CMS) proposed a 6.4% estimated decrease to home health payments for fiscal year 2026, effective January 1, 2026.
• CMS finalized a net increase of 2.6% to hospice payments for fiscal year 2026, effective October 1, 2025.
• Enhabit consolidated 13 branches (8 Home Health, 5 Hospice) during 2025 and does not anticipate additional branch closures for the remainder of 2025.
• The Covenant Adjustment Period for the company's credit facilities ended on May 9, 2025, and Enhabit was in compliance with the financial covenants as of September 30, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated a strong financial turnaround with positive net income and robust Hospice segment growth. However, the significant proposed cuts to Home Health Medicare payments introduce considerable future uncertainty and risk, tempering overall sentiment.

Positives

• Net income attributable to Enhabit, Inc. swung to a profit of $11.1 million in Q3 2025 from a loss of $110.2 million in Q3 2024.
• Operating income significantly improved to $16.8 million in Q3 2025 from a loss of $98.0 million in Q3 2024.
• Hospice segment net service revenue increased by 20.0% in Q3 2025, driven by a 12.6% increase in average daily census and a 6.7% improvement in revenue per patient day.
• Adjusted EBITDA increased to $27.0 million in Q3 2025 from $24.5 million in Q3 2024.
• Successful sale of an investment in TVG Holdings, LLC generated approximately $21 million in proceeds and a $19.3 million gain.
• Used $20.0 million of investment sale proceeds to reduce debt under the Credit Agreement.
• CMS finalized a 2.6% net increase to hospice payments for fiscal year 2026, effective October 1, 2025.
• The company was in compliance with all financial covenants under its Credit Facilities as of September 30, 2025, following the end of the Covenant Adjustment Period.

Negatives

• CMS proposed a 6.4% estimated decrease to home health payments for fiscal year 2026, effective January 1, 2026, which could significantly reduce reimbursement rates for the industry.
• Home Health segment net service revenue slightly decreased by 0.2% in Q3 2025 and 2.8% for the nine months ended September 30, 2025.
• Home Health Segment Adjusted EBITDA decreased by 7.1% in Q3 2025 and 10.0% for the nine months ended September 30, 2025.
• Home Health Medicare admissions decreased by 5.1% and completed episodes decreased by 2.5% for Q3 2025.
• The company consolidated 13 branches (8 Home Health, 5 Hospice) during 2025 due to financial performance analysis.
• Management cannot guarantee continued compliance with financial covenants throughout the next year, despite current compliance.

Risks

• Ability to execute on strategic plans.
• Regulatory and other developments impacting the markets for services, particularly changes in Medicare reimbursement rates.
• General economic conditions.
• Changes in the episodic versus non-episodic mix of payers, patient case mix, and payment methodologies.
• Ability to attract and retain key management personnel and healthcare professionals.
• Potential disruptions or breaches of information systems (company, vendors, payers, and other contract counterparties).
• Outcome of litigation and regulatory proceedings, including potential undisclosed qui tam lawsuits under the False Claims Act.
• Quality performance and ratings.
• Ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures.
• Ability to successfully integrate technology in operations.
• Ability to control costs, particularly labor and employee benefit costs, especially during periods of inflation or labor shortages.
• Non-compliance with credit facility covenants could result in an event of default, permitting lenders to accelerate debt maturity and foreclose on collateral.

Future Outlook

CMS finalized a 2.6% net increase to hospice payments for fiscal year 2026, effective October 1, 2025. However, CMS proposed a 6.4% estimated decrease to home health payments for fiscal year 2026, effective January 1, 2026, which the company is actively advocating against. Management is evaluating additional cost control and operating efficiency options, including deploying a VPE management pilot program to all Home Health branches during Q4 2025. The company does not anticipate further branch closures for the remainder of 2025 and expects to incur approximately $3.3 million in cash tax liability from the TVG sale in future periods. Maintenance capital expenditures for 2025 are projected to be between $4 to $5 million. While currently compliant with financial covenants, management cannot guarantee continued compliance throughout the next year.

Management Comments

• "We will continue to analyze financial performance at the branch level, but we do not anticipate additional branch closures or consolidation for the remainder of 2025."
• "Based on our analysis of the 2026 Hospice Final Rule, we expect the impact to us to be in line with the 2.6% increase for services provided beginning October 1, 2025."
• "Based on our analysis of the proposed 2026 Home Health Rule, we expect the impact to us to be in line with the 6.4% decrease, if implemented as proposed."
• "We are actively engaged in advocacy efforts in response to the proposed 2026 Home Health Rule, which, if finalized as proposed, could result in a significant reduction in reimbursement rates for our industry."
• "Due to the severity of the proposed cuts in the 2026 Home Health Rule, management is evaluating additional options for further cost control and operating efficiencies, including, among other things, advanced clinically based management of visits per episode (VPE)."
• "Management continually evaluates the Company's expected compliance with the covenants described above and takes all appropriate steps to proactively renegotiate such covenants when appropriate."

Industry Context

The healthcare industry, particularly home health and hospice services, is heavily influenced by government reimbursement rates, primarily from Medicare. The proposed 6.4% cut to home health payments for FY2026 highlights ongoing regulatory pressure and reimbursement uncertainty in this segment, a common challenge for providers. Conversely, the 2.6% increase in hospice payments suggests a more stable or favorable outlook for that segment. The company's focus on cost control, operating efficiencies, and VPE management reflects a strategic response to these industry-specific reimbursement and labor cost pressures, which are prevalent across the labor-intensive healthcare sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Enhabit's performance against global industry benchmarks.

Corporate Governance

Legal Proceedings

• The company is routinely subject to various legal actions, proceedings, claims, and regulatory audits and investigations in the highly regulated healthcare industry.
• No pending legal proceedings are believed to be material to the company as of September 30, 2025.
• There is a risk of undisclosed qui tam lawsuits being filed against the company under the False Claims Act.
• The company incurred third-party legal fees associated with the suit 'Enhabit, Inc. et al. v. Nautic Partners IX, L.P. et al.', asserting claims for breach of fiduciary duty, aiding and abetting, and usurpation of corporate opportunity arising from actions involving former officers.

Related Party Transactions

• The company entered into several agreements with Encompass Health Corporation (Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement, Transition Services Agreement) in connection with its separation on July 1, 2022. The Transition Services Agreement expired on March 31, 2024.
• Sold its investment interest in TVG Holdings, LLC (which owned Medalogix, a former related party) for approximately $21 million on March 19, 2025.
• Incurred costs of approximately $1.2 million for the nine months ended September 30, 2025, and $1.2 million (three months) and $3.6 million (nine months) for the periods ended September 30, 2024, for the usage of Medalogix's analytics platforms while Medalogix was a related party.

Stakeholder Impact

• Shareholders: Positive impact from the significant net income turnaround, debt reduction, and investment sale gain. Negative impact from the proposed substantial cuts to Home Health Medicare reimbursement and ongoing regulatory uncertainty.
• Employees: Potential impact from cost control initiatives and branch consolidations. Continued focus on recruiting and retaining qualified personnel is highlighted.
• Customers (Patients): Potential impact from branch consolidations and changes in service delivery models (e.g., VPE management) due to cost efficiency efforts.
• Creditors: Improved financial performance, cash position, and debt reduction are positive. Compliance with credit facility covenants is maintained, but future compliance uncertainty is noted.
• Suppliers: Potential impact from cost control initiatives and renegotiation of service contracts.

Next Steps

• Actively engage in advocacy efforts in response to the proposed 2026 Home Health Rule.
• Deploy the VPE management pilot program to all Home Health branches during Q4 2025.
• Management will continue to evaluate expected compliance with credit facility covenants and proactively renegotiate such covenants when appropriate.
• Monitor developments regarding the final 2026 Home Health Rule.
• Pay approximately $3.3 million of cash tax liability from the TVG sale in future periods.
• Spend approximately $4 to $5 million for maintenance capital expenditures during 2025.

Key Dates

Recommendation

Enhabit's Q3 2025 results show a strong rebound in net income and robust growth in its Hospice segment, alongside effective debt reduction and a profitable investment sale. These factors suggest improved operational execution and financial health. However, the proposed 6.4% cut to Home Health Medicare payments for FY2026 represents a significant headwind for a major portion of the company's revenue. While management is actively engaged in advocacy and cost control, the uncertainty surrounding this regulatory change warrants a cautious approach. Investors should hold the stock and closely monitor the finalization of the Home Health rule and the company's ability to mitigate its potential negative impact.

Keywords

Home Health, Hospice, Healthcare Services, Medicare, Medicare Advantage, SEC Filing, 10-Q, Financial Results, Reimbursement Rates, Adjusted EBITDA, Debt Management, Regulatory Risk, EHAB